Loading organizations...
Based in Jakarta, Indonesia, Asaren operates a digital biobank and bioinformatics platform that provides AI-powered clinical-genomic analytics alongside direct-to-consumer DNA testing kits. The enterprise leverages artificial intelligence to process genetic data, generating over 360 personalized reports covering health risks, pharmacogenomics, oncogenomics, and ancestry. These genomic insights are utilized to support healthcare decision-making for local clinicians, medical researchers, regulatory bodies, and individual consumers throughout the Southeast Asian market. Prior to its strategic exit, the health-tech startup secured $8.15 million in an oversubscribed seed funding round backed by prominent venture capital firms including East Ventures, Marcy Venture Partners, and Kejora Capital. In March 2024, the genomic data business was acquired by regional healthcare provider Diagnos Laboratories for a valuation of approximately $24 million. Asaren was founded in 2016 by chief executive officer Aloysius Liang.
Asaren has raised $8.0M across 1 funding round.
Asaren has raised $8.0M in total across 1 funding round.
Asa Ren is an Indonesian biotech company specializing in AI-powered precision medicine and clinical-genomic analytics. It builds a digital biobank and bioinformatics platform offering pharmacogenomics and oncogenomics reports to support personalized treatments, drug discovery, and healthcare decision-making for clinicians, researchers, regulators, and over 10,000 users.[1][2] Serving primarily the healthcare sector with a focus on diverse Asian populations, Asa Ren addresses gaps in clinico-genomic data dominated by Caucasian-centric databases, enabling predictions of treatment performance and life-saving discoveries through real-world evidence and 21,000 committed research samples.[2][3] Founded in 2016 in Jakarta, it raised $8.15M before being acquired by Diagnos Laboratories in March 2024, marking strong growth in digital health and AI.[1]
Asa Ren was founded in 2016 in Jakarta, Indonesia, by CEO Aloysius Lian, who leads its focus on AI-driven healthcare insights tailored to Asian demographics.[1][3] The idea emerged from recognizing the need for clinico-genomic databases representing diverse Asian populations, unlike global ones centered on Caucasians, to advance drug discovery and personalized medicine in underserved regions.[3] Early traction built through partnerships like the Oneasa Biobank project with Indonesian hospital groups and clinicians, amassing 21,000 research samples and scaling to thousands of monthly users.[2][3] A pivotal push came from international expansion efforts, such as collaborating with freelancers for Japan market entry—Japan's advanced pharma sector and status as the world's second-largest healthcare market—to secure knowledge transfer and sponsorships.[3]
Asa Ren rides the AI in digital health wave, particularly precision medicine and genomics, amid booming demand for personalized treatments in Asia's underserved markets.[1][2] Timing aligns with Japan's mature pharma ecosystem and Indonesia's rising HealthTech adoption, where genomic research lags but offers high growth potential—Japan's market scale provides validation and partnerships for knowledge transfer.[3] Market forces like real-world evidence needs, diverse population data gaps, and AI infrastructure advancements favor it, positioning Asa Ren to influence Southeast Asia's startup ecosystem by strengthening local biobanks and clinician tools post-acquisition.[1][3] Its inclusion in CB Insights' Digital Health and AI collections underscores its role in global tech-enabled healthcare transformation.[1]
Post-2024 acquisition by Diagnos Laboratories, Asa Ren will likely deepen synergies in service expansion, leveraging combined strengths for broader healthcare impact and new revenue from AI-genomics.[1] Trends like AI-driven drug discovery, Asia-centric real-world evidence, and Japan-Indonesia collaborations will shape its path, potentially accelerating the Oneasa Biobank and pharma sponsorships.[2][3] Influence may evolve from niche innovator to regional leader in precision medicine, enhancing Diagnos's position while unlocking personalized treatments for millions—echoing its origins as a "secret book" to minimize health risks and maximize potential.[4]
Asaren has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in February 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 1, 2023 | $8M Seed | — | Accel, Caffeinated Capital, Hercules Capital, Insight Partners, Khosla Ventures, Prosperity7 Ventures, Sound Ventures, TOP Harvest Capital, Upside Partnership, Y Combinator, George Hoyem, Janis Krums, Karl Jacob, Roger Ehrenberg, RON Garret, SAM Altman, TOM Mcinerney | Announced |
Asaren has raised $8.0M in total across 1 funding round.
Asaren's investors include Accel, Caffeinated Capital, Hercules Capital, Insight Partners, Khosla Ventures, Prosperity7 Ventures, Sound Ventures, Top Harvest Capital, Upside Partnership, Y Combinator, George Hoyem, Janis Krums.
